Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.J Hepatol. 2016; 65: 719-726
- HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma.J Hepatol. 2018; 68: 25-32
- High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis.J Hepatol. 2016; 65: 1070-1071
- Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma.J Hepatol. 2016; 65: 859-860
- Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: first, do no harm by withdrawing treatment.J Hepatol. 2016; 65: 862-864
- Direct antiviral agents and risk for HCC early recurrence: much ado about nothing.J Hepatol. 2016; 65: 861-862
- Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma.Hepatology. 2013; 58: 150-157
- Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: issue of the interval between HCC treatment and antiviral therapy.J Hepatol. 2017; 66: 464
- The impact of direct antiviral agents on the development and recurrence of hepatocellular carcinoma.Liver Int. 2017; 37: 136-139